Astrazeneca Receives Japan Approval for CFC-free Corticosteroid Inhaler for Paediatric Asthma.Tokyo, Japan, Aug 3, 2006 - (JCN) - Astrazeneca announced on July 27 that it had received approval for its Pulmicort Turbuhaler, an inhaler for pediatric asthma infants from 6 months to under 5 years old, frrom the Japanese Ministry of Health, Labor and Welfare. Pulmicort Turbuhaler is taken once daily with an electronic nebuliser that change liquid medicines into a fine mist for easy breathing in. The three main efficiency of the drug include reduced inflammation in the airways of lungs, reduced asthma attack frequency by 50% for 2 weeks use and as much as 75% during a 12 week period, and reduced sleep distraction of 61.4%. The drug has been recommended in the guidelines for Management of treatment for Pediatric Patients of Bronchial bronchial /bron·chi·al/ (brong´ke-al) pertaining to or affecting one or more bronchi. bron·chi·al (br ng k Asthma, set forth by the Japanese Society of Pediatric Allergy and Clinical Immunology. AstraZeneca expect rapid use of the medication. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||

ng
k
Printer friendly
Cite/link
Email
Feedback
Reader Opinion